Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001181431-13-035719
Filing Date
2013-06-19
Accepted
2013-06-19 15:53:04
Documents
1
Period of Report
2013-06-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 rrd383960.html 4  
1 FORM 4 rrd383960.xml 4 4367
  Complete submission text file 0001181431-13-035719.txt   5790
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 4152444990
TITAN PHARMACEUTICALS INC (Issuer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O TITAN PHARMACEUTICALS INC 400 OYSTER POINT BLVD S SAN FRANCISCO CA 94080
Business Address
BHONSLE SUNIL (Reporting) CIK: 0001180755 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-27436 | Film No.: 13922007